News
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
The biopharmaceutical giant AstraZeneca is considering moving their stock listing from the London Stock Exchange to the US in ...
London’s FTSE 100 was flat at 8,824.61 in quiet afternoon trade on Friday, with US markets closed for Independence Day.
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback